Leerink Partnrs Has Bullish Forecast for BSX Q2 Earnings

Boston Scientific Corporation (NYSE:BSX) – Investment analysts at Leerink Partnrs boosted their Q2 2026 earnings estimates for shares of Boston Scientific in a research report issued to clients and investors on Tuesday, September 9th. Leerink Partnrs analyst M. Kratky now expects that the medical equipment provider will post earnings of $0.86 per share for the quarter, up from their prior estimate of $0.84. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share. Leerink Partnrs also issued estimates for Boston Scientific’s Q4 2026 earnings at $0.94 EPS and FY2026 earnings at $3.43 EPS.

A number of other equities research analysts also recently issued reports on the stock. Truist Financial boosted their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Morgan Stanley upped their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, May 16th. Citigroup reaffirmed a “buy” rating and set a $125.00 target price (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $115.00 target price on shares of Boston Scientific in a research note on Wednesday, May 28th. Finally, Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $118.00 to $125.00 in a research note on Monday. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $117.79.

Boston Scientific Price Performance

Boston Scientific stock opened at $105.32 on Wednesday. The company’s 50 day simple moving average is $104.88 and its 200-day simple moving average is $102.24. The company has a market capitalization of $156.06 billion, a price-to-earnings ratio of 62.69, a price-to-earnings-growth ratio of 2.60 and a beta of 0.65. Boston Scientific has a 1 year low of $80.64 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business’s revenue was up 22.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of BSX. Investment Management Corp VA ADV acquired a new position in shares of Boston Scientific in the 4th quarter valued at $25,000. Sunbeam Capital Management LLC acquired a new position in shares of Boston Scientific in the 4th quarter valued at $26,000. 1248 Management LLC acquired a new position in shares of Boston Scientific in the 1st quarter valued at $26,000. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $26,000. Finally, Y.D. More Investments Ltd acquired a new stake in Boston Scientific during the 1st quarter worth $27,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director owned 2,081 shares of the company’s stock, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock worth $18,397,457. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.